Exercise-Induced Bronchoconstriction
BreAnna Kinghorn, MD
Introduction/Etiology/Epidemiology
•Exercise-induced bronchoconstriction (EIB) involves acute, transient airway narrowing that occurs during and after exercise.
•EIB is most often defined by ≥10% decline in forced expiratory volume in 1 second (FEV1) at spirometry after exercise provocation.
•EIB occurs in 90% of individuals with asthma.
•EIB also can occur in individuals without a known diagnosis of asthma.
•Prevalence of EIB is higher in the competitive athlete population (30%–70%) than the nonathlete population (≤10%).
Pathophysiology
•Breathing dry and/or cold air causes airway narrowing via osmotic and thermal consequences of evaporative water loss from the airway surface.
•Dry or cold air in the distal airways causes hyperemia of bronchial vasculature and airway edema, which further causes airway narrowing.
•Airway narrowing causes cough.
•Although the events that trigger EIB and the role of inflammatory cells are not fully understood, a hyperosmolar environment is thought to trigger the release of inflammatory mediators, including histamine, tryptase, and leukotrienes from eosinophils and mast cells.
•Several studies have demonstrated that individuals who are prone to EIB have increased levels of exhaled nitric oxide, increased airway leukotriene levels, greater expression of mast cell genes, and/or peripheral eosinophilia.
Clinical Features
•Clinical manifestations can range from mild impairment to severe bronchospasm and, rarely, respiratory failure.
•Symptoms include coughing, wheezing, chest tightness, and dyspnea.
•More subtle symptoms include fatigue, abdominal discomfort, poor performance, and avoidance of activities.
•Exercise duration for a minimum of 5–8 minutes at 80% of maximum predicted oxygen consumption typically generates bronchospasm.
• Symptoms peak 5–10 minutes after exercise ceases and can last 60–90 minutes.
Differential Diagnosis
(Note: Children may have EIB [Figure 41-1] in addition to any of the disorders listed here.)
•Unrecognized or poorly controlled asthma
•Anxiety
Figure 41-1. Diagnostic flowchart for exercise-induced bronchoconstriction (EIB). Reprinted with permission from Krafczyk MA, Asplund CA. Exercise-induced bronchoconstriction: diagnosis and management. Am Fam Physician. 2011;84(4):427– 434. Copyright © 2011 American Academy of Family Physicians. All Rights Reserved.
•Vocal cord dysfunction
•Exercise-induced laryngomalacia
•Exercise-induced anaphylaxis
•Exercise-induced reflux
•Central airway obstruction arrhythmias
•Pulmonary or cardiac shunt
Diagnostic Considerations
Comprehensive History and Physical Examination
•Obtaining a history alone has been shown to lead to under- and over-diagnosis of EIB.
—Rule out other etiologic origins, including vocal cord dysfunction, arrhythmias, and pulmonary or cardiac shunt.
—Obtain a complete family history, including asthma or relatives with atopy.
Pulmonary Function Testing
While spirometry is the most important pulmonary function test, there are other tests that can be considered when evaluating a patient with exercise-related respiratory symptoms, including some that are more sensitive and/or less effort-dependent than spirometry alone. For the purpose of this review, discussion will be limited to the use of spirometry in the diagnosis of EIB.
Spirometry
•All patients with suspected EIB should perform spirometry.
—Assess the patient for baseline airway obstruction (ratio of FEV1 to forced vital capacity up to the lower limit of normal for age).
Bronchodilator Responsiveness
•Identify bronchodilator responsiveness, defined as an increase of ≥12% in FEV1 after inhalation of a short-acting bronchodilator.
Bronchoprovocation Techniques
•FEV1 decrease ≥10% from a pre-exercise level is diagnostic of EIB, with an FEV1 decline of ≥50% considered to indicate severe EIB.
•Indirect testing: Exercise, eucapnic voluntary hyperpnea, inhaled powdered mannitol, or nebulized hypertonic saline (see Table 41-1)
—Elicits inflammatory response to release mediators and provokes airway smooth muscle constriction
—Measurements obtained 5, 10, 15, and 30 minutes after exercise
• Direct challenges: Methacholine or histamine
—Acts directly with airway smooth muscle receptors to cause constriction independent of airway inflammation
Table 41-1. Indirect Testing (Performed in a Pulmonary Function Laboratory) for the Diagnosis of Exercise-Induced Bronchoconstriction | |
Test | Description |
Exercise | Laboratory or field based Involves 2 min of warm up to 85% MVV, then sustaining for 6 min FEV1 measured pre-exercise and at 5, 10, 15, and 30 min after exercise in the laboratory setting FEV1 measured before and after exercise in the field |
Eucapnic voluntary hyperpnea | Voluntary breathing of hypercapnic air (4.5%–5% CO2, 21% O2) at 85% MVV for 6 min FEV1 measured pre-exercise and at 5, 10, 15, and 30 min after exercise |
Mannitol | Inhalation of dry powder mannitol with measurement of FEV1 1 min after inhalation Mannitol dose doubled until FEV1 change ≥15%, in between dose decrease ≥10% FEV1 or maximum cumulative dose |
Hypertonic saline | Inhalation of 4.5% hypertonic saline with FEV1 measured every 60 s Repeat dosing until FEV1 change ≥15% |
FEV1, forced expiratory volume in 1 second; MVV, maximal voluntary ventilation.
Management
Pharmacological and nonpharmacological management strategies are summarized in Box 41-1.
Pharmacological Therapy
•Pretreatment before exercise
—Short-acting β-agonists
▪First-line treatment for EIB
▪Two puffs 15 minutes prior to exercise
▪Peak bronchodilation at 15–60 minutes, coverage for 3 hours
—Leukotriene receptor antagonist: Montelukast therapy offers protection against EIB and improvement of decrease of FEV1 after exercise
▪Onset of action within 2 hours, with continued benefit for ≤24 hours
▪Often suggested in individuals with allergic rhinitis
—Daily inhaled corticosteroids should be used in patients with refractory or daily symptoms or asthma
▪Long-term control of asthma with anti-inflammatory medication reduces airway responsiveness and frequency and severity of EIB
▪May take 1–2 weeks after therapy initiation to see maximal improvement
•Additional therapies
—Antihistamine may be helpful in individuals with allergies.
Box 41-1. Management Strategies for Exercise-Induced Bronchoconstriction
Pharmacological | Nonpharmacological |
Short-acting β-agonists | Adequate warm-up |
Inhaled corticosteroids | Avoidance of triggers |
Long-acting β2-agonists or inhaled corticosteroids | Nasal breathing |
Mask or face device | |
Leukotriene receptor antagonists | Dietary modifications (based on limited evidence) |
Antihistamines |